Recent advances and future directions in preclinical research of argininevasopressin (AVP) receptor blocker conivaptan in the context of stroke

Neural Regeneration Research

Volumn 11, Issue 3, 2016, Pages 392-393

  Zeynalov, Emil ^a   Jones, Susan M ^a  

^a SWEDISH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 4; COLLAGENASE; CONIVAPTAN; SODIUM; TOLVAPTAN; VASOPRESSIN; VASOPRESSIN V1A RECEPTOR; VASOPRESSIN V2 RECEPTOR;

ANEURYSM; BLOOD BRAIN BARRIER; BRAIN BLOOD FLOW; BRAIN EDEMA; CEREBRAL SALT WASTING; CEREBROVASCULAR ACCIDENT; DRUG SCREENING; HUMAN; HYPERVOLEMIA; HYPONATREMIA; INTERSTITIAL FLUID; MORTALITY; NONHUMAN; NOTE; OSMOLALITY; PROTEIN EXPRESSION; SUBARACHNOID HEMORRHAGE; THROMBOCYTE AGGREGATION; VASOCONSTRICTION; VASODILATATION; WATER RETENTION;

EID: 84962176157     PISSN: 16735374     EISSN: 18767958     Source Type: Journal    
DOI: 10.4103/1673-5374.179038     Document Type: Note

References (12)

1. Deen PM, Verdijk MA, Knoers NV, Wieringa B, Monnens LA, van Os CH, van Oost BA (1994) Requirement of human renal water channel aquaporin-2 for vasopressin-dependent concentration of urine. Science 264:92-95.
2. Fenton RA, Moeller HB (2008) Recent discoveries in vasopressin-regulated aquaporin-2 trafficking. Prog Brain Res 170:571-579.
3. Hedna VS, Bidari S, Gubernick D, Ansari S, Satriotomo I, Khan AA, Qureshi AI (2014) Treatment of stroke related refractory brain edema using mixed vasopressin antagonism: a case report and review of the literature. BMC Neurol 14:213.
4. Holmes CL, Landry DW, Granton JT (2003) Science review: Vasopressin and the cardiovascular system part 1--receptor physiology. Crit Care 7:427-434.
5. Kleindienst A, Dunbar JG, Glisson R, Marmarou A (2013) The role of vasopressin V1A receptors in cytotoxic brain edema formation following brain injury. Acta Neurochir (Wien) 155:151-164.
6. Li-Ng M, Verbalis JG (2009) Conivaptan: Evidence supporting its therapeutic use in hyponatremia. Core Evid 4:83-92.
7. Liu X, Nakayama S, Amiry-Moghaddam M, Ottersen OP, Bhardwaj A (2010) Arginine-vasopressin V1 but not V2 receptor antagonism modulates infarct volume, brain water content, and aquaporin-4 expression following experimental stroke. Neurocrit Care 12:124-131.
8. Manaenko A, Fathali N, Khatibi NH, Lekic T, Hasegawa Y, Martin R, Tang J, Zhang JH (2011) Arginine-vasopressin V1a receptor inhibition improves neurologic outcomes following an intracerebral hemorrhagic brain injury. Neurochem Int 58:542-548.
9. Rauen K, Trabold R, Brem C, Terpolilli NA, Plesnila N (2013) Arginine vasopressin V1a receptor-deficient mice have reduced brain edema and secondary brain damage following traumatic brain injury. J Neurotrauma 30:1442-1448.
10. Saleem S, Yousuf I, Gul A, Gupta S, Verma S (2014) Hyponatremia in stroke. Ann Indian Acad Neurol 17:55-57.
11. Zeynalov E, Jones SM, Seo JW, Snell LD, Elliott JP (2015) Arginine-vasopressin receptor blocker conivaptan reduces brain edema and blood-brain barrier disruption after experimental stroke in mice. PLoS One 10:e0136121.
12. Zeynalov E, Chen CH, Froehner SC, Adams ME, Ottersen OP, Amiry-Moghaddam M, Bhardwaj A (2008) The perivascular pool of aquaporin-4 mediates the effect of osmotherapy in postischemic cerebral edema. Crit Care Med 36:2634-2640.